News | May 25, 2026
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
